Stock Chart

ENTX

$3.11 -3.42%
Score: 46.8 HOLD
Pro
Screener
Vol: 0.44x (vs SPY: 0.6x | vs QQQ: 0.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Nov 13, 2026
Bull Pennant weak / forming — below our quality gate quality 53/100
A Bull Pennant is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks up 70% of the time (n=1,684). Measured-move targets failed our backtest — none shown.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About ENTX - Entera Bio Ltd. Ordinary Shares

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed …

Key Statistics

Market Cap $561M

More ENTX Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This ENTX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ENTX's price movements with trendlines, gamma walls, and key support/resistance levels.